Sunday, October 04, 2015 3:54:33 PM
One example of concern identified with supplement use might be creatine used by athletes to help muscle growth. Creatine was loosely implicated in causing kidney failure in a group of wrestlers that trained in a hot room and became dehydrated and many were hospitalized with issues including kidney failure. Creatine was implicated as a cause even though they had signs of a condition called exertional rhabdomyolysis which was likely responsible for the kidney issues.
As a practitioner treating athletes, out of an abundance of caution, I recommend that they remain well hydrated IF they choose to use creatine, as many do anyway. There are 2 reasons that I mention the caution. One is to educate folks on the data, another is to mitigate any liability for the team doctor and the athlete's school.
There are few similarities between this example and Sucanon. One that comes to mind, though, is that my role is not to recommend,because I am not a regulatory entity, but to educate based on available data and scientific principles. Another is to do with the MDA endorsement of Sucanon. First it is a fact that the Mexican government regulatory body approved Sucanon for sale without a prescription. Second MDA endorsed Sucanons use and made a standard statement that they include for every endorsement that they recommend checking with your doctor before using it. This is very similar to the caution on the OTC 200mg ibuprofen in my own medicine cabinet that says among other cautions "ask a doctor or pharmacist before use if you are : under a doctors care for any serious condition, taking any other drug, taking aspirin for heart attack or stroke..." It also says "ask a doctor before taking if you are on a diuretic, have high blood pressure, heart disease, kidney disease, liver cirrhosis, or asthma..." So before a big deal is made of "not recommending" or "on the advice of a doctor" I suggest that we think about the ibuprofen warnings and for goodness sake call your doctor before taking ibuprofen with any of the above issues...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM